We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New Antigen-Based COVID-19 Rapid Test Format Analyzes 500 Samples per Hour and Detects SARS-CoV-2 Infection in 10 Minutes

By LabMedica International staff writers
Posted on 20 May 2021
A new antigen-based detection technique could be used to analyze as many as 500 samples per hour and was able to diagnose a viral infection almost as accurately as PCR tests in a recently completed study.

Researchers at the University of Helsinki (Helsinki, Finland) have developed a new rapid assay principle for viral antigen detection, applying it to diagnosing SARS-CoV-2 infections. More...
The test is based on a phenomenon known as time-resolved Förster resonance energy transfer (TR-FRET), where energy travels between two light-sensitive molecules when they are close enough to each other. TR-FRET makes it possible to measure viral particles or the body’s own proteins by using what are known as ‘mix and read’-type tests on complex biological samples, such as serum or even whole blood. In fact, the researchers have previously applied the procedure in the rapid detection of antibodies.

In practice, the TR-FRET solution of the new SARS-CoV-2 rapid test functions like this: a nasopharyngeal swab taken from the test subject is mixed in a test solution which contains antibodies that recognise the SARS-CoV-2 nucleoprotein or spike protein. The antibodies marked with fluorescent labels bind with SARS-CoV-2 particles, forming molecular assemblies, or complexes, whose existence can be confirmed/detected by using a TR-FRET assay. The results come in roughly 10 minutes later: the formation of any complexes demonstrates, to a high degree of certainty, an infection caused by SARS-CoV-2 in the test subject.

The researchers investigated the functioning of the rapid test using 48 specimens which had been selected on the basis of a positive SARS-CoV2 PCR test, with varying concentrations of viral RNA.

“We demonstrated in our study that a technique based on the TR-FRET phenomenon can be used to diagnose SARS-CoV-2 infections in clinical specimens”, said Jussi Hepojoki, docent of virology and Academy of Finland research fellow at the University of Helsinki. “We demonstrated that the technique we have developed was able to detect almost all positive specimens (37/38), from which we were able to isolate SARS-CoV-2 in cell culture. In other words, the carriers were likely to continue to spread the virus at the time of sample collection.”

In contrast, 10 of the selected group of positive SARS-CoV-2 samples produced a positive result in a PCR test even though virus isolation was no longer possible. None of these samples yielded a positive antigen test result. According to Hepojoki, the PCR tests available are sensitive enough to detect coronavirus even when the sample collection has not been optimal. At the same time, this sensitivity can result in cases of positive PCR test results when the infection itself has been eliminated.

Hepojoki says that another benefit of the new rapid test developed by the researchers is its safety for testers: in practice, the virus becomes inactivated soon after being mixed in the test solution. He says that rapid antigen-based tests could be particularly useful for testing not only travelers, but also people at educational institutions. A TR-FRET reader roughly the size of a desktop computer is needed for the test, making it possible, at least in theory, to carry out testing almost anywhere. In addition to the novel coronavirus, the assay principle can be utilized to detect other respiratory infections or basically any molecule: the only thing needed is an antibody capable of identifying the target molecule.

Related Links:
University of Helsinki


Gold Member
SARS-CoV-2 PCR Test
Macurra SARS-CoV-2 PCR Kit
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.